12:00 AM
 | 
Oct 15, 2007
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALTY-0501: Phase II data

In a double-blind Phase II trial in 160 patients, ALTY-0501 missed the primary endpoint of a significant reduction in central corneal damage compared with placebo following exposure to a controlled adverse environment. Compared with placebo,...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >